These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35863797)

  • 21. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy.
    Verwer MC; Waissi F; Mekke JM; Dekker M; Stroes ESG; de Borst GJ; Kroon J; Hazenberg CEVB; de Kleijn DPV
    Atherosclerosis; 2022 May; 349():196-203. PubMed ID: 34857353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia.
    Tomoi Y; Soga Y; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamauchi Y; Miyashita Y; Tazaki J; Nobuyoshi M
    Cardiovasc Interv Ther; 2013 Oct; 28(4):374-82. PubMed ID: 23756936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease.
    Kim GS; Seo J; Kim BG; Jin MN; Lee HY; Kim BO; Byun YS
    Yonsei Med J; 2022 Apr; 63(4):333-341. PubMed ID: 35352884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    Szarek M; Bhatt DL; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Ketchum SB; Lira Pineda A; Doyle RT; Steg PG;
    J Am Coll Cardiol; 2024 Apr; 83(16):1529-1539. PubMed ID: 38530686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events.
    Guédon AF; De Freminville JB; Mirault T; Mohamedi N; Rance B; Fournier N; Paul JL; Messas E; Goudot G
    JAMA Netw Open; 2022 Dec; 5(12):e2245720. PubMed ID: 36480201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Frailty and Age on Clinical Outcomes in Patients Who Underwent Endovascular Therapy.
    Nishikawa K; Ebisawa S; Miura T; Kato T; Yusuke K; Abe N; Yokota D; Yanagisawa T; Senda K; Wakabayashi T; Oyama Y; Karube K; Itagaki T; Yui H; Maruyama S; Nagae A; Sakai T; Okina Y; Nakazawa S; Tsukada S; Saigusa T; Okada A; Motoki H; Kagoshima M; Kuwahara K
    J Endovasc Ther; 2022 Dec; 29(6):845-854. PubMed ID: 34969317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Goto S; Ohman EM; Elbez Y; Sritara P; Baumgartner I; Banerjee S; Creager MA; Bhatt DL;
    Eur Heart J; 2014 Nov; 35(41):2864-72. PubMed ID: 24585266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl.
    Piao ZH; Jin L; Kim JH; Ahn Y; Kim YJ; Cho MC; Kim CJ; Kim HS; Liu B; Jeong MH;
    Am J Cardiol; 2017 Jul; 120(2):174-180. PubMed ID: 28532771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.
    Volis I; Saliba W; Jaffe R; Eitan A; Zafrir B
    Am J Cardiol; 2020 Aug; 128():28-34. PubMed ID: 32650921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review.
    Masson W; Lobo M; Barbagelata L; Molinero G; Bluro I; Nogueira JP
    Vasc Med; 2022 Aug; 27(4):385-391. PubMed ID: 35466849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
    Matsushita K; Hibi K; Komura N; Kimura Y; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
    J Cardiol; 2020 Jul; 76(1):66-72. PubMed ID: 32037254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events.
    Thomas PE; Vedel-Krogh S; Nielsen SF; Nordestgaard BG; Kamstrup PR
    J Am Coll Cardiol; 2023 Dec; 82(24):2265-2276. PubMed ID: 38057068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin use in patients with peripheral arterial disease.
    Harris SK; Roos MG; Landry GJ
    J Vasc Surg; 2016 Dec; 64(6):1881-1888. PubMed ID: 27871503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization.
    Zierfuss B; Höbaus C; Feldscher A; Hannes A; Mrak D; Koppensteiner R; Stangl H; Schernthaner GH
    Atherosclerosis; 2022 Dec; 363():94-101. PubMed ID: 36280470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.
    Heart Protection Study Collaborative Group
    J Vasc Surg; 2007 Apr; 45(4):645-654; discussion 653-4. PubMed ID: 17398372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries.
    Gao S; Ma W; Huang S; Lin X; Yu M
    Am J Cardiol; 2021 Aug; 152():34-42. PubMed ID: 34130824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease.
    Sanchez Muñoz-Torrero JF; Rico-Martín S; Álvarez LR; Aguilar E; Alcalá JN; Monreal M;
    Atherosclerosis; 2018 Sep; 276():10-14. PubMed ID: 30006322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.